Clinical Trial Update: An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016) [Phase 2]

View source ↗

Summary

An extension protocol allows eligible melanoma patients from a prior talimogene laherparepvec study to continue treatment; results for the extension were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Imlygic (Talimogene laherparepvec)

Snippet

Sponsor: BioVex Limited | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2015-12-17